In a patient with T2DM, semaglutide reduces cardiovascular events (SUSTAIN-6 trial). The mechanism of GLP-1 agonist-mediated cardiovascular protection that is most well-supported is:
- A Beta-cell preservation preventing hypoglycemic episodes that trigger sympathetic-mediated cardiac events
- B Anti-atherosclerotic action via reduction of VCAM-1 and macrophage foam-cell formation in the arterial wall through GLP-1 receptor signaling in macrophages ✓
- C Direct GLP-1 receptor-mediated natriuresis and blood pressure reduction through renal tubular effects
- D Decreased post-prandial triglyceride-rich lipoprotein production from the small intestine reducing atherogenic lipid burden
Explanation
GLP-1 receptors are expressed on vascular endothelium, macrophages, and smooth muscle cells. Activation reduces expression of adhesion molecules like VCAM-1 and MCP-1, decreasing monocyte recruitment to the arterial wall; it also reduces foam cell formation by promoting cholesterol efflux via ABCA1 pathways in macrophages. Additionally, direct endothelial GLP-1R signaling activates NO synthase, improving endothelial function. Multiple cardiovascular outcome trials (LEADER, SUSTAIN-6, HARMONY) show GLP-1 agonists reduce MACE. Hypoglycemia reduction and modest BP/weight effects contribute but are considered secondary mechanisms.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.